---
title: "Enliven Therapeutics CFO Sells 1,000 Shares"
date: "2025-02-08 08:10:00"
summary: "Reporter NameHohl BenjaminRelationshipCHIEF FINANCIAL OFFICERTypeSellAmount$22,524SEC FilingForm 4Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, sold 1,000 shares of common stock on February 5, 2025, at a weighted average price of $22.5244 per share, totaling $22,524. Following the transaction, Hohl directly owns 13,000 shares of the company. The sale was conducted under..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

| Reporter Name | Hohl Benjamin |
| --- | --- |
| Relationship | CHIEF FINANCIAL OFFICER |
| Type | Sell |
| Amount | $22,524 |
| SEC Filing | [Form 4](https://www.sec.gov/Archives/edgar/data/1882764/000141588925003405/xslF345X05/form4-02082025_120242.xml) |

Enliven Therapeutics' Chief Financial Officer, Benjamin Hohl, sold 1,000 shares of common stock on February 5, 2025, at a weighted average price of $22.5244 per share, totaling $22,524. Following the transaction, Hohl directly owns 13,000 shares of the company. The sale was conducted under a Rule 10b5-1 trading plan adopted on June 26, 2023.

SEC Filing: [Enliven Therapeutics, Inc. [ ELVN ] - Form 4 - Feb. 07, 2025](https://www.sec.gov/Archives/edgar/data/1882764/000141588925003405/xslF345X05/form4-02082025_120242.xml)

[TradingView](https://www.tradingview.com/news/tradingview:074ed2ecd9517:0-enliven-therapeutics-cfo-sells-1-000-shares/)
